EP
ACAD icon

Edgestream Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Edgestream Partners’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.17M Buy
283,301
+91,973
+48% +$2.02M 0.21% 147
2026
Q1 		$4.26M Sell
191,328
-124,911
-39% -$2.99M 0.14% 282
2025
Q4 		$8.45M Buy
316,239
+82,394
+35% +$1.97M 0.24% 99
2025
Q3 		$4.99M Buy
233,845
+122,701
+110% +$2.9M 0.15% 252
2025
Q2 		$2.4M Sell
111,144
-47,964
-30% -$892K 0.07% 488
2025
Q1 		$2.64M Sell
159,108
-105,282
-40% -$1.91M 0.09% 417
2024
Q4 		$4.85M Buy
264,390
+45,061
+21% +$727K 0.21% 165
2024
Q3 		$3.37M Buy
219,329
+128,372
+141% +$2.14M 0.15% 232
2024
Q2 		$1.48M Buy
90,957
+29,051
+47% +$469K 0.07% 423
2024
Q1 		$1.14M Buy
61,906
+23,998
+63% +$595K 0.06% 467
2023
Q4 		$1.19M Buy
37,908
+28,205
+291% +$674K 0.09% 390
2023
Q3 		$202K Sell
9,703
-74,467
-88% -$2.02M 0.02% 786
2023
Q2 		$2.02M Buy
+84,170
New +$1.87M 0.18% 189

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Edgestream Partners's ACAD Position: Q2 2026 in Review

Edgestream Partners increased its Acadia Pharmaceuticals (ACAD) stake by 48% in Q2 2026, buying an estimated $2.02M and bringing the position to 283,301 shares worth $7.17M. The position accounts for 0.21% of the portfolio, ranked #147.

Edgestream Partners first reported a position in ACAD in Q2 2023 and has held it in 13 quarters since. The position peaked at $8.45M in Q4 2025. 352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Edgestream Partners held 283,301 shares of Acadia Pharmaceuticals worth $7.17M as of Q2 2026.
  • Edgestream Partners bought 91,973 Acadia Pharmaceuticals shares in Q2 2026, an estimated $2.02M.
  • Acadia Pharmaceuticals made up 0.21% of Edgestream Partners's portfolio in Q2 2026, its #147 holding.
  • Edgestream Partners first reported a position in Acadia Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • Edgestream Partners's Acadia Pharmaceuticals position peaked at $8.45M in Q4 2025.
  • 352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Edgestream Partners's 13F filing for Q2 2026, filed 11 Aug 2026.